https://crcblueprint.com/trials-eligibility/metastatic/https://crcblueprint.com/trials-eligibility/biomarker-none/https://crcblueprint.com/trials-eligibility/first-line/https://crcblueprint.com/trials-eligibility/msi-high/https://crcblueprint.com/trials-eligibility/locally-advanced/https://crcblueprint.com/trials-eligibility/braf-v600e/https://crcblueprint.com/trials-eligibility/rectal/https://crcblueprint.com/trials-eligibility/colon/https://crcblueprint.com/trials-eligibility/previously-treated/https://crcblueprint.com/trials-eligibility/her2/https://crcblueprint.com/trials-eligibility/kras-g12d/https://crcblueprint.com/trials-eligibility/ras-wild-type/https://crcblueprint.com/trials-eligibility/pik3ca/https://crcblueprint.com/trials-eligibility/ras-mutated/